Amneal Pharmaceuticals, Inc..
American publicly traded generics and specialty pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 24
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Truist Financial increased its target price for Amneal Pharmaceuticals, Inc.Some support1 report
-
Amneal Pharmaceuticals received a Buy rating from Truist Financial on August 1, 2025, noting that the company benefits from Trump-era tariffs and AI trends.Some support1 report
-
Goldman Sachs initiated coverage on Amneal Pharmaceuticals, noting its headquarters in Bridgewater and Gautam Patel as director.Speculative1 report
-
Chirag was appointed as a Co-Chief Executive Officer of Amneal Pharmaceuticals, Inc.Some support1 report
-
Knight entered into an agreement on August 5, 2025, regarding CREXONT rights with Amneal Pharmaceuticals, Inc.Some support2 reports
-
The FDA approved the Brekiya® autoinjector from Amneal Pharmaceuticals on August 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Amneal Pharmaceuticals, Inc. this week
News at the entities that move Amneal Pharmaceuticals, Inc. most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Amneal Pharmaceuticals, Inc.
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Amneal Pharmaceuticals, Inc.
-
Truist Financial Mentioned togetherMarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.Moves Amneal Pharmaceuticals, Inc.
-
Knight TransactionalA company named Knight operates a restaurant from a 15th-century building located in Glastonbury, which is based in Somerset.Moves Amneal Pharmaceuticals, Inc.
-
Leerink partners Mentioned togetherAnalyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Moves Amneal Pharmaceuticals, Inc.
-
Nasdaq Shared contextApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Amneal Pharmaceuticals, Inc.
Connections
The 7 strongest of 24, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates and approves pharmaceutical products developed by Amneal.
-
SEC Structural
Amneal Pharmaceuticals is subject to formal regulation and disclosure requirements by the SEC.
-
Knight Transactional
Knight and Amneal entered a formal agreement for the exclusive commercialization rights of CREXONT®.
-
Truist Financial Mentioned together
Truist Financial provides investment ratings and target price forecasts for Amneal Pharmaceuticals.
-
John Kiely Structural
John Kiely serves as a Director of Amneal Pharmaceuticals, Inc., and the evidence confirms he sold company shares.
-
Leerink partners Mentioned together
The relationship is based on shared market research coverage and analyst ratings.
-
Nasdaq Shared context
Amneal Pharmaceuticals is listed and traded on the Nasdaq exchange.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
7 events- Amneal Pharmaceuticals highlighted positive study results from Kashiv BioSciences and is currently seeking FDA approval for a biosimilar product.
- Truist Financial increased its target price for Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals received a Buy rating from Truist Financial on August 1, 2025, noting that the company benefits from Trump-era tariffs and AI trends.
- Goldman Sachs initiated coverage on Amneal Pharmaceuticals, noting its headquarters in Bridgewater and Gautam Patel as director.
- Chirag was appointed as a Co-Chief Executive Officer of Amneal Pharmaceuticals, Inc.
- Knight entered into an agreement on August 5, 2025, regarding CREXONT rights with Amneal Pharmaceuticals, Inc.
- The FDA approved the Brekiya® autoinjector from Amneal Pharmaceuticals on August 5, 2025.